This Week in Urology — Aug 21, 2026

Welcome to This Week in Urology. This week we're covering 10 notable papers spanning benign prostatic obstruction and the surgical management of the prostate, advanced prostate cancer risk stratification and therapy, and a cluster of studies on peri-operative practice — imaging, antibiotics, opioids, and even remote robotic surgery. Let's dive in.

We start with benign prostatic obstruction, where European Urology Focus publishes the one-year results of the VAPEUR randomised trial from Vincendeau and colleagues, comparing Rezum water vapour thermal therapy against combination pharmacotherapy with an alpha-blocker plus a five-alpha-reductase inhibitor [1]. This was a pragmatic multicentre trial in 151 sexually active men with symptomatic obstruction. At one year, symptom scores improved by roughly eleven points with water vapour therapy versus about six points with drugs — a difference of just under five points on the International Prostate Symptom Score, and quality-of-life improvement also favoured the procedure. Sexual function scores stayed essentially flat in both arms, and importantly, superiority for preserving sexual function was not demonstrated once missing data were accounted for, so that particular selling point remains unproven. Surgical retreatment was uncommon after vapour therapy, around one percent versus nine percent with medication, though the vapour arm had more men going back onto drugs, and the combined retreatment endpoint did not reach statistical significance. The trade-off is adverse events: forty percent with the procedure versus twenty-eight percent with pharmacotherapy, and serious adverse events in about one in eight men treated with vapour therapy, mostly procedure-related and mostly resolved by a year. So the honest framing for a patient is better symptom relief and fewer trips to the operating theatre later, at the cost of a higher early complication burden.

Staying with the prostate but moving to the acute setting, World Journal of Urology reports a single-surgeon series from Peterson and colleagues of twenty-four emergency holmium laser enucleations performed as an inpatient for refractory haematuria [8]. These were not easy cases — median enucleated volume was 156 grams, several patients had already failed cystoscopic fulguration during the same admission, and eleven had prior prostate interventions including transurethral resection, photoselective vaporisation, or artery embolisation. Three quarters of patients passed a voiding trial on day one, all were catheter-free at three months, and none required a further procedure, though ten patients needed transfusion. It is retrospective and it reflects one experienced enucleator's hands, but it makes a reasonable case that definitive enucleation, rather than repeated clot evacuation, is the way out of intractable prostatic bleeding. Alongside that, European Urology Focus carries a provocative opinion piece from Seikkula and colleagues asking whether we should still be sending transurethral resection chips for histology at all [3]. Their argument is that incidental cancer found in resection specimens is usually low grade, transition zone tumours behave more favourably than peripheral zone disease, and routine processing is expensive and generates anxiety and follow-up that many men do not need. They stop short of recommending abandonment, instead calling for formal evaluation of a risk-adapted strategy in men with low pre-operative suspicion. Worth flagging as a coming debate rather than a change to make tomorrow.

Turning to advanced prostate cancer, World Journal of Urology publishes a post hoc analysis of the TITAN trial by Hori and colleagues, testing whether combining the CHAARTED volume criteria with the LATITUDE risk criteria sharpens prognosis in metastatic castration-sensitive disease [4]. Across just over a thousand patients, the integrated classification into double low, intermediate, and double high groups gave modestly better discrimination for overall survival than either system alone. Apalutamide improved survival across most subgroups, but in the double low group with synchronous metastases there was no clear benefit — and the authors are appropriately cautious, noting very wide confidence bounds and calling this exploratory and in need of prospective validation. I would not use it to withhold intensification today, but it does point at a genuinely low-risk subgroup where the absolute gain may be small. Complementing that, European Urology Focus offers a practical consultation guide to PSMA-targeted radioligand therapy from McKenzie and colleagues [2]. The interesting content is beyond the standard six cycles: adaptive approaches including dose escalation or fractionation based on tumour volume, pausing treatment in exceptional responders, and retreating at relapse. It is a review, not new evidence, but it is a useful framework for the conversation you will increasingly be having in clinic.

Three papers this week deal with how we stage, operate, and prescribe. In BJU International, Vallecilla and colleagues report a systematic review and meta-analysis of fluorodeoxyglucose PET-CT for inguinal and pelvic nodal staging in penile squamous cell carcinoma, pooling eight studies for the quantitative analysis [6]. Sensitivity and specificity both sat around eighty-five percent, but the negative likelihood ratio of 0.25 is the number that matters clinically — a negative scan does not reliably exclude nodal disease. The practical message is that PET-CT is a confirmatory test, and in clinically node-negative men it does not replace surgical staging of the groin. Also in BJU International, De Naeyer and colleagues describe a prospective pilot of telesurgical robot-assisted radical prostatectomy between two Belgian institutions — ten remote cases matched against ten contemporaneous on-site procedures [7]. All ten remote operations were completed without intraoperative adverse events and without local takeover, with median operative time around 155 minutes, mean network latency near eleven milliseconds, and one transient connection interruption that had no clinical consequence. Pathological and early functional outcomes fell within the range of the on-site comparison group. Twenty patients is a feasibility signal, not evidence of equivalence, but it establishes the safety framework that larger trials will need. And BJU International also publishes a Delphi consensus from Lo Re and colleagues on urological issues in masculinising genital surgery, with twenty-seven experienced gender-affirming surgeons reaching agreement on seventy-five of eighty-three statements [5]. They declined to set an upper age limit for metoidioplasty or phalloplasty, but identified body mass index above about twenty-five, diabetes, smoking, and cardiovascular disease as relevant risk factors, with a Charlson Comorbidity Index of three or more a relative contraindication to phalloplasty though not to metoidioplasty. For urethral complications they favoured staged reconstruction at a six-month interval, with perineostomy considered in high-risk patients. No consensus was reached on suspending testosterone peri-operatively — an open question.

Finally, two studies in Urology challenge reflexive prescribing habits. Neeman and colleagues reviewed 435 children undergoing pyeloplasty at two paediatric centres and found post-operative urinary tract infection in just under one in five [9]. Drainage configuration was the dominant driver: about fifteen percent with an internal double-J stent alone, rising to roughly twenty-seven percent with an externalised stent and thirty-five percent with a combined internal stent plus nephrostomy, and both externalised configurations remained independent risk factors after adjustment. Pelvic reduction was protective. Crucially, discharge antibiotic prophylaxis, given to about four in ten children, showed no association with infection in any drainage subgroup. The parallel finding comes from Hoang and colleagues, who analysed more than twelve thousand outpatient urological operations at a single institution [10]. About a third of patients went home with an opioid prescription, and those patients had roughly double the odds of an opioid refill in the first month, with elevated odds persisting out to ninety days — independent of opioid-naive status, recovery-room opioid use, pain score at discharge, or procedure type. It is retrospective and residual confounding is possible, but the direction is consistent: just-in-case prescribing appears to create demand rather than meet it.

If you only have time for one paper this week, make it the VAPEUR randomised trial in European Urology Focus [1]. It is the first pragmatic head-to-head randomised comparison of water vapour thermal therapy against the medical regimen most of our patients are actually on, and it gives you real numbers — for both benefit and harm — to put on the table in clinic.

Here are the key takeaways from this week in Urology. Water vapour thermal therapy beat combination drug therapy on symptoms and quality of life at one year, but with more early adverse events and unproven superiority for sexual function. Emergency holmium enucleation looks like a durable solution for refractory prostatic haematuria in experienced hands. In metastatic castration-sensitive disease, combining volume and risk criteria refines prognosis, and the lowest-risk synchronous group may derive less benefit from intensification — exploratory, and not yet actionable. A negative PET-CT does not clear the groin in penile cancer. And two papers converge on the same lesson: after paediatric pyeloplasty, choose your drain rather than reaching for prophylactic antibiotics, and after outpatient urological surgery, stop writing the just-in-case opioid script.

That's your roundup for This Week in Urology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And a quick rating on Apple Podcasts or Spotify helps other physicians discover the show.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.